Dr. reddy's financial report and auditors report;

Dr. Reddy’s Laboratories Financial Report and Auditors’ Report for FY25

Financial Performance (FY25):

Revenue: Dr. Reddy’s reported consolidated revenues of ₹325,535 million for FY25, marking a robust 17% year-on-year growth.
Net Profit: The consolidated net profit for the year stood at ₹56,544 million (₹5,655 crore), reflecting a 2% increase from the previous year.
EBITDA: The company achieved its highest-ever EBITDA at ₹92,133 million, with an EBITDA margin of 28.3%.
Key Growth Drivers: Double-digit top-line growth was recorded across all major markets—the US, Europe, Emerging Markets, and India. The US business benefited from new launches and stable sales of key products like Lenalidomide. The India business grew by 8.4%, supported by strong performance in Dermatology, Respiratory, Vaccines, and Urology segments.
Strategic Initiatives: FY25 saw expansion through the acquisition of Nicotinell and other Nicotine Replacement Therapy (NRT) brands, especially strengthening the company’s presence in Europe. Partnerships included a nutrition venture with Nestle in India and new product launches in Russia and the US.

Auditors’ Report (FY25):

The independent auditors issued an unqualified (clean) report on Dr. Reddy’s consolidated financial statements for the year ended March 31, 2025, indicating that the financial statements present a true and fair view in accordance with the applicable accounting standards.
The audit was conducted by SR Batliboi & Associates LLP, who confirmed that the financial statements were free from material misstatements and complied with all regulatory requirements.
The results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on May 9, 2025.

Corporate Governance and Reporting:

Dr. Reddy’s FY25 Integrated Annual Report adheres to international reporting standards, including the Global Reporting Initiative (GRI) and SEBI’s Business Responsibility and Sustainability Report (BRSR) requirements.
The company’s governance framework and risk management practices are detailed in the annual report, reflecting its commitment to transparency and responsible business conduct.

Summary Table: Key FY25 Financials

Recent Posts